Abstract:Importance: Epilepsy is the most common neurological disorder of childhood. Identifying genetic diagnoses underlying epilepsy is critical to developing effective therapies and improving outcomes. Most children with non-acquired (unexplained) epilepsy remain genetically unsolved, and the utility of genome sequencing after nondiagnostic exome sequencing is unknown. Objective: To determine the diagnostic (primary) and clinical (secondary) utility of genome sequencing after nondiagnostic exome sequencing in individuals with unexplained pediatric epilepsy. Design: This cohort study performed genome sequencing and comprehensive analyses for 125 participants and available biological parents enrolled from August 2018 to May 2023, with data analysis through April 2024 and clinical return of diagnostic and likely diagnostic genetic findings. Clinical utility was evaluated. Setting: Pediatric referral center Participants: Participants with unexplained pediatric epilepsy and previous nondiagnostic exome sequencing; biological parents when available Exposure(s): Short-read genome sequencing and analysis Main Outcome(s) and Measure(s): Primary outcome measures were the diagnostic yield of genome sequencing, defined as the percentage of participants receiving a diagnostic or likely diagnostic genetic finding, and the unique diagnostic yield of genome sequencing, defined as the percentage of participants receiving a diagnostic or likely diagnostic genetic finding that required genome sequencing. The secondary outcome measure was clinical utility of genome sequencing, defined as impact on evaluation, treatment, or prognosis for the participant or their family. Results: 125 participants (58 [46%] female) were enrolled with median age at seizure onset 3 [IQR 1.25, 8] years, including 44 (35%) with developmental and epileptic encephalopathies. The diagnostic yield of genome sequencing was 7.2% (9/125), with diagnostic genetic findings in five cases and likely diagnostic genetic findings in four cases. Among the solved cases, 7/9 (78%) required genome sequencing for variant detection (small copy number variant, three noncoding variants, and three difficult to sequence small coding variants), for a unique diagnostic yield of genome sequencing of 5.6% (7/125). Clinical utility was documented for 4/9 solved cases (44%). Conclusions and Relevance: These findings suggest that genome sequencing can have diagnostic and clinical utility after nondiagnostic exome sequencing and should be considered for patients with unexplained pediatric epilepsy.

Clinical Utility of Exome Sequencing and Reinterpreting Genetic Test Results in Children and Adults With Epilepsy

Next Generation Sequencing in Children with Unexplained Epilepsy: A Retrospective Cohort Study.

High Diagnostic Yield and Clinical Utility of Next-Generation Sequencing in Children with Epilepsy and Neurodevelopmental Delays: A Retrospective Study

The role of genetic testing in adult patients with unexplained epilepsy

Next-generation Sequencing Improves Treatment Efficacy and Reduces Hospitalization in Children with Drug-Resistant Epilepsy

Next-generation sequencing testing in children with epilepsy reveals novel clinical, diagnostic and therapeutic implications

Reanalysis of Whole Exome Sequencing Data in Patients with Epilepsy and Intellectual Disability/mental Retardation

Utility of Genome Sequencing After Nondiagnostic Exome Sequencing in Unexplained Pediatric Epilepsy

Clinical application of whole-exome sequencing analysis in childhood epilepsy

Next-generation sequencing in pediatric-onset epilepsies: Analysis with target panels and personalized therapeutic approach

Pediatric Epilepsy Genetic Testing Results and Long-term Seizure Freedom

Clinical Application of Targeted Next-Generation Sequencing Panels and Whole Exome Sequencing in Childhood Epilepsy

Validation of targeted next-generation sequencing panels in a cohort of polish patients with epilepsy: assessing variable performance across clinical endophenotypes and uncovering novel genetic variants

A retrospective study of the yield of next‐generation sequencing in the diagnosis of developmental and epileptic encephalopathies and epileptic encephalopathies in 0–12 years aged children at a single tertiary care hospital in South India

Spectrum of Leukodystrophy and Genetic Leukoencephalopathy in Indian Population Diagnosed by Clinical Exome Sequencing and Clinical Utility

Clinically significant changes in genes and variants associated with epilepsy over time: implications for re-analysis

C.1 Utility of genetic testing in the pre-surgical evaluation of children with drug-resistant epilepsy

Exome sequencing as first-tier genetic testing in infantile-onset pharmacoresistant epilepsy: diagnostic yield and treatment impact

Genetic Diagnosis Spectrum and Multigenic Burden of Exome-Level Rare Variants in a Childhood Epilepsy Cohort

Genetic Variants Identified from Epilepsy of Unknown Etiology in Chinese Children by Targeted Exome Sequencing

Genetic diagnoses in pediatric patients with epilepsy and comorbid intellectual disability.